Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9159 USD | -1.52% | +1.20% | -35.04% |
May. 13 | Transcript : Lucid Diagnostics Inc., Q1 2024 Earnings Call, May 13, 2024 | |
May. 13 | Lucid Diagnostics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-35.04% | 45.63M | - | ||
+75.35% | 12.55B | B- | ||
-23.01% | 7.51B | C+ | ||
+8.35% | 6.74B | C- | ||
+14.40% | 5.47B | D+ | ||
-14.85% | 4.89B | B | ||
+32.74% | 4.74B | - | ||
-23.06% | 2.9B | C | ||
+55.06% | 2.49B | C- | ||
+0.25% | 1.99B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- LUCD Stock
- Ratings Lucid Diagnostics Inc.